切换至 "中华医学电子期刊资源库"
高级检索
中华普外科手术学杂志(电子版)

中华普外科手术学杂志(电子版) ›› 2021, Vol. 15 ›› Issue (05) : 554 -557. doi: 10.3877/cma.j.issn.1674-3946.2021.05.024

论著

蛋白质组学RPPA技术筛选乳腺癌患者预后相关血清分子标志物的研究
张爽1,†(), 林冰1, 周平1, 刘沙1, 刘玉1, 罗志飞2   
  1. 1. 570100　海南海口，海南医学院第一附属医院肿瘤中心
    2. 570100　海南海口，海南医学院第一附属医院病理科
  • 出版日期:2021-10-26
  • 通信作者: 张爽

Screening the prognosis-related serum molecular markers of breast cancer based on reverse phase protein array

Shuang Zhang1,†(), Bing Lin1, Ping Zhou1, Sha Liu1, Yu Liu1, Zhifei Luo2   

  1. 1. Department of Oncology, the first affiliated hospital of Hainan medical university, Hainan 570100, China
    2. Department of pathology, the first affiliated hospital of Hainan medical university, Hainan 570100, China
  • Published:2021-10-26
  • Corresponding author: Shuang Zhang
  • Supported by:
    Key Project of Hainan Provincial Research and Development Program of Science and Technology Department(ZDYF2018158)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张爽, 林冰, 周平, 刘沙, 刘玉, 罗志飞. 蛋白质组学RPPA技术筛选乳腺癌患者预后相关血清分子标志物的研究[J]. 中华普外科手术学杂志(电子版), 2021, 15(05): 554-557.

Shuang Zhang, Bing Lin, Ping Zhou, Sha Liu, Yu Liu, Zhifei Luo. Screening the prognosis-related serum molecular markers of breast cancer based on reverse phase protein array[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(05): 554-557.

目的

探究影响乳腺癌患者预后相关的血清分子标志物。

方法

选择2013年6月至2015年2月经病理确诊的乳腺癌患者126例作为研究对象，患者术后随访5年，采用蛋白质组学反向蛋白阵列(RPPA)技术筛选患者预后相关的血清分子标志物。使用统计学软件SPSS 22.0进行统计学处理，采用Pearson相关分析探究筛选出的蛋白质与患者临床资料间的相关性；采用单因素Cox回归分析筛选影响患者预后的相关蛋白，多因素Cox回归分析探究筛选出的蛋白、临床资料与患者预后间的相关性，得到影响患者预后的独立危险因素，P<0.05表示有统计学意义。

结果

通过RPPA技术对37种血清蛋白质的检测，单因素回归分析，丝氨酸羟甲基转移酶2(SHMT2)、丙氨酸-丝氨酸-半胱氨酸转运载体2(ASCT2)高表达是影响患者5年总生存率以及无复发生存率的显著相关因素。SHMT2、ASCT2高表达与患者肿瘤大小、TNM分期、病理分级以及雌激素受体(ER+)、孕激素受体(PR+)之间均具有显著的正相关性。多因素Cox回归分析，SHMT2、ASCT2高表达也是影响患者预后的独立危险因素。

结论

高水平ASCT2和SHMT2表达与乳腺癌患者不良预后有关，可能作为乳腺癌潜在的治疗靶点。

关键词: 乳腺肿瘤, 蛋白质组学, 反向蛋白阵列, 预后, 存活率分析
Objective

To explore the prognosis molecular markers in serum of patients with breast neoplasms.

Methods

126 patients diagnosed as breast cancer from June 2013 to February 2015 were enrolled and were followed up for 5 years after the operation. The proteomics reverse phase protein array (RPPA) technology was used to screen the biomarkers associated with the prognosis of the patients. Statistical analysis were performed by using SPSS 22.0 software. The correlation of the candidate proteins and the clinical data were analyzed by using Pearson correlation analysis; Univariate Cox analyses were used to evaluate the proteins that affect the prognosis of patients, then multivariate Cox analyses were used to analyze the correlation of the candidate proteins, clinical data and the prognosis of the patients, to obtain the independent risk factors affecting the prognosis of the patients. A P value of <0.05 was considered as statistically significant difference.

Results

37 serum proteins were detected by RPPA , univariate Cox analyses showed that the high expression of serine hydroxymethyl transferase 2(SHMT2) and alanine-serine-cysteine transporter 2 (ASCT2) were significantly associated with the 5 years recurrence-free survival and overall survival. The high expression of SHMT2 and ASCT2 had a significant positive correlation with the tumor size, TNM stage, pathological grade, estrogen receptor (ER+ ) and progesterone receptor (PR+ ). Multivariate Cox analyses showed that the high expression of SHMT2 and ASCT2 were also independent risk factors affecting the prognosis of patients.

Conclusion

High levels of ASCT2 and SHMT2 expression are related to the poor prognosis of breast neoplasms, which might be the potential therapeutic targets for breast cancer.

Key words: Breast neoplasms, Proteomics, Reverse phase protein array, Prognosis, Survival analysis
表1 RPPA筛选的影响乳腺癌患者术后5年总生存率的抗体
变量 B SE Wald HR(95%CI) P值
SHMT2 0.519 0.605 11.631 2.43(1.62~5.68) <0.001
ASCT2 0.881 0.294 8.052 2.17(1.42~4.81) <0.001
表2 RPPA筛选影响乳腺癌患者术后5年无复发生存率的抗体
变量 B SE Wald HR(95%CI) P值
SHMT2 0.685 0.492 12.628 2.67(1.96~7.19) <0.001
ASCT2 0.761 0.361 10.249 2.33(1.70~5.38) <0.001
GAPDH -0.6118 0.559 6.519 1.82(1.44~3.86) <0.001
PKM2 0.516 0.546 5.046 1.36(1.15~2.46) 0.004
FH 0.884 0.406 6.035 1.58(1.30~3.16) 0.001
CAD 0.623 0.351 17.019 2.82(2.12~9.67) <0.001
表3 SHMT2、ASCT2与乳腺癌患者的基本临床资料相关因素分析
变量 SHMT2 ASCT2
r值 P值 r值 P值
年龄 0.352 0.218 0.346 0.152
肿瘤大小 0.452 0.042 0.401 0.038
TNM分期 0.484 0.031 0.416 0.027
病理分级 0.643 0.038 0.447 0.019
ER 0.506 0.007 0.532 0.003
PR 0.472 0.016 0.016 0.012
表4 影响乳腺癌患者术后5年总生存率的多因素Cox回归分析
变量 B SE Wald HR(95%CI) P值
年龄 0.256 0.203 7.652 2.41(1.76~5.40) <0.001
TNM分期 1.925 0.318 6.586 1.75(1.43~2.54) <0.001
SHMT2 0.815 0.511 4.918 1.54(1.21~2.16) 0.028
ASCT2 0.226 0.184 3.903 1.35(1.11~1.85) 0.041
表5 影响乳腺癌患者术后5年无复发生存率的多因素Cox回归分析
变量 B SE Wald HR(95%CI) P值
年龄 1.205 0.226 7.162 2.01(1.10~6.17) <0.001
TNM分期 0.816 0.314 5.922 1.60(1.31~3.84) <0.001
SHMT2 0.552 0.262 4.427 1.49(1.09~3.54) 0.035
ASCT2 0.319 0.176 4.216 1.28(1.11~2.85) 0.046
[1]
李凡，周军. 功能磁共振成像在乳腺癌诊断中的应用进展[J]. 中国肿瘤外科杂志，2020, 12(1)：79-83.
[2]
Zuo T, Wanqing Chen. Advances in research on population-based female breast cancer survival in China[J]. Chinese Journal of Clinical Oncology, 2016, 43(14): 639-642.
[3]
Zingarello A, Mazouni C, Rivera S, et a1. Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer[J]. Breast, 2017, 26(35): 162-168.
[4]
Labrie M, Fang Y, Kendsersky ND, et al. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance[J]. Adv Exp Med Biol, 2019，1188: 251-266.
[5]
Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence[J]. Breast Cancer Res Treat, 2016，159(3): 395-406.
[6]
Ascolani G, Lio P. Modeling breast cancer progression to bone: how driver mutation order and metabolism matter[J]. BMC Med Genomics, 2019，12(Suppl 6): 106.
[7]
Asnani A, Shi X, Farrell L, et al. Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer[J]. J Cardiovasc Transl Res, 2020，13(3): 349-356.
[8]
Yoneten KK, Kasap M, Akpinar G, et al. Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism[J]. Cancer Genomics Proteomics, 2019，16(5): 377-397.
[9]
Kresbach GM, Pawlak M. High Precision RPPA: Concept, Features, and Application Performance of the Integrated Zeptosens Platform[J]. Adv Exp Med Biol, 2019，1188: 31-59.
[10]
Ye JX, Huang Q, Xu J, et al. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth[J]. J Cancer Res Clin Oncol, 2018，144(5): 821-833.
[11]
曹丽，石岩硕，庞国勋. 谷氨酰胺在神经系统疾病的临床应用研究进展[J]. 解放军医药杂志，2020, 32(6)：113-116.
[12]
Broer A, Gauthier-Coles G, Rahimi F, et al. Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells[J]. J Biol Chem, 2019，294(11): 4012-4026.
[13]
Broer A, Rahimi F, Broer S. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells[J]. J Biol Chem, 2016，291(25): 13194-13205.
[14]
Liu Y, Zhao TL, Li ZZ, et al. The role of ASCT2 in cancer: A review[J]. Eur J Pharmacol, 2018，837: 81-87.
[15]
Jiang HL, Zhang N, Tang TZ, et al. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy[J]. Pharmacol Res, 2020，158: 104844.
[16]
Wang L, Liu Y, Zhao TL, et al. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer[J]. Phytomedicine, 2019，57: 117-128.
[17]
Bernhardt S, Bayerlova M, Vetter M, et al. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors[J]. Breast Cancer Res, 2017，19(1): 112.
[18]
Lee GY, Haverty PM, Li L, et al. Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes[J]. Cancer Res, 2014，74(11): 3114-3126.
[19]
Marrocco I, Altieri F, Rubini E, et al. Shmt2: A Stat3 Signaling New Player in Prostate Cancer Energy Metabolism[J]. Cells, 2019，8(9)：1048.
[20]
Tong J, Krieger JR, Taylor P, et al. Cancer proteome and metabolite changes linked to SHMT2[J]. PLoS One, 2020，15(9): e0237981.
[21]
Yang X, Wang Z, Li X, et al. SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation[J]. Cancer Res, 2018，78(2): 372-386.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[11] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[12] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号